Phase 3 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been confirmed by a tissue biopsy to have Diffuse Large B-cell Lymphoma (DLBCL) or Follicular grade IIIb lymphoma, as classified by the 2017 World Health Organization guidelines.
• People aged 65 or older.
• People who have had a full geriatric (older adult health) assessment completed before any treatment begins.
• People whose general health and ability to carry out daily activities falls within a certain range on a standard medical scale (confirm with trial site).
• People whose doctors have determined them suitable to receive a standard chemotherapy treatment plan that includes a drug type called an anthracycline (either R-CHOP or R-miniCHOP).
• People who have never previously received treatment for DLBCL or Follicular grade IIIb lymphoma.
• People whose lymphoma is classified at any stage from Stage I to Stage IV.
• People who have at least one area of lymphoma that is large enough to be measured on a scan — either a mass of at least 1.5 cm on a CT scan, or a metabolically active area visible on a PET scan.
• People whose blood level of Vitamin D is 40 ng/ml or below.
• People whose blood counts (white blood cells, platelets) meet minimum levels set by the trial, unless low counts are caused by the lymphoma itself.
• People whose kidney function meets the trial's minimum requirement, unless any reduction is caused by the lymphoma.
• People whose liver function meets the trial's minimum requirement, unless any reduction is caused by the lymphoma.
• People whose heart pumping function is above 50%, as measured by an echocardiogram (heart ultrasound).
• People who are expected to live at least 6 months.
• People who are willing and able to sign a consent form after being informed about the trial, before any study procedures begin.
• People who are able to attend all required trial visits and follow the study schedule.
• Men who agree to use an acceptable form of contraception throughout the study and for 3 months after the last dose of treatment, and who agree not to donate sperm during this time.

Who may not be able to join:

• People whose lymphoma is a different type than DLBCL or Follicular grade IIIb lymphoma, including a high-grade form known as "double-hit" lymphoma (involving specific gene changes called MYC, BCL2, and/or BCL6).
• People who are already taking Vitamin D supplements at a dose higher than 10,000 units per week as part of their standard care.
• People who have suspected or confirmed spread of lymphoma to the brain or spinal cord.
• People who have a medical reason that prevents them from receiving the drug rituximab.
• People who have a medical reason that prevents them from taking Vitamin D supplements — for example, having too much calcium or phosphate in their blood.
• People who have received any cancer treatment (such as chemotherapy, immunotherapy, radiation, or experimental treatments) within 14 days before the first study dose.
• People with a significant history of serious neurological, psychiatric, hormonal, metabolic, immune, or liver conditions that could interfere with participation or with giving informed consent.
• People who have had another active cancer within the past 2 years — although certain early-stage or fully treated cancers may be exceptions (confirm with trial site).
• People with other serious uncontrolled medical conditions, including active or uncontrolled infections (viral, bacterial, or fungal), or chronic Hepatitis B or Hepatitis C that requires treatment.

Important: Always verify eligibility with the trial site directly before applying.